Recent Updates
Recently added Catalysts
SRPT

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences: Co
Price reaction · baseline $76.02 (2022-03-01 close) · hit after-hours · clean, no other SRPT news in the window
day 0 close
+4.7%
day 1 · peak
+7.2%
day 3
+5.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:
Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:10 p.m. E.T.
Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. E.T.
Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day on Thursday, March 31, 2022 at 12 p.m. E.T.
The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Last updated: Mar 2, 2022